TIM-3-Next Generation Immunotherapy Competitive Landscape and Market Forecast 2035

TIM-3 is a co-inhibitory receptor that is expressed on IFN-γ-producing T cells, FoxP3+ Treg cells and innate immune cells (macrophages and dendritic cells) where it has been shown to suppress their responses upon interaction with their ligand(s). TIM-3 has gained prominence as a potential candidate for cancer immunotherapy, where it has been shown that in vivo blockade of TIM-3 with other check-point inhibitors enhances anti-tumor immunity and suppresses tumor growth in several preclinical tumor models

The TIM-3-Next Generation Immunotherapy market is expected to generate USD 1,218 Million in the year 2035.
The key players in TIM-3-Next Generation Immunotherapy market include Symphogen, GlaxoSmithKline, Novartis, Bristol-Myers Squibb, Ono Pharmaceuticals, BeiGene, Incyte Biosciences, Agenus, Roche, Eli Lilly and others.

For more information visit:
https://www.delveinsight.com/report-store/TIM-3-next-generation-immunotherapy-competitive-landscape